EquitiesAmerica.com
Educational content — not investment advice

Merck & Company, Inc.

MRKNYQHealthcare
Visit Website

Data as of April 18, 2026

Key Metrics

Market Cap

$293.30B

P/E Ratio

16.27

P/B Ratio

5.58

Dividend Yield

2.94%

Return on Equity

0.37%

Debt / Equity

95.96

Insider Ownership

0.06%

Institutional Own.

81.38%

Employees

73,000

Sector & Industry

Sector

Healthcare

Industry

Drug Manufacturers - General

About Merck & Company, Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Ownership Snapshot

Insider0.06%
Institutional81.38%
Public / Other18.56%

Source: Yahoo Finance / SEC filings. For full details, see the Holdings page.

Explore More

Disclaimer: All data on this page is historical and sourced from publicly available databases including SEC EDGAR and Yahoo Finance. EquitiesAmerica.com is an educational publisher and does not provide personalized investment guidance, securities analysis, or trading recommendations. Past data does not predict future results. Please consult a registered investment professional before making any financial decision. Read full disclaimer.